Pharmacology, Toxicology and Pharmaceutical Science
Adalimumab
33%
Antipsoriasis Agent
7%
Apremilast
50%
Arthritis
7%
Biological Product
75%
Combination Therapy
50%
Disease
25%
Etanercept
33%
Guselkumab
10%
Interleukin 17 Antibody
50%
Interleukin 23
30%
Interleukin 23 Antibody
50%
Interleukin 23p19
50%
Ixekizumab
50%
Psoriasis
100%
Psoriatic Arthritis
58%
Risankizumab
10%
Secukinumab
50%
Tildrakizumab
10%
Ustekinumab
50%
Medicine and Dentistry
Actinic Keratosis
50%
Adverse Event
20%
Apremilast
50%
Biological Product
40%
Clinical Trial
10%
Cohort Analysis
10%
Combination Therapy
10%
Dermatology
50%
Diseases
5%
Drug Delivery System
10%
Guselkumab
10%
Immunosuppressant
8%
Infection
10%
Interleukin 17
10%
Interleukin 23
30%
Interleukin 23 Antibody
50%
Interleukin 23p19
50%
Outpatient
50%
Precursor
5%
Prevalence
50%
Psoriasis
50%
Psoriasis Area and Severity Index
28%
Psoriasis Vulgaris
10%
Public Health
5%
Risankizumab
10%
Squamous Cell Carcinoma
11%
Tildrakizumab
10%
Treatment Response
10%
